AUTOLOGOUS STEM CELL-BASED GENE THERAPY OFFERS AN INNOVATIVE SOLUTION FOR TREATING INHERITED BLOOD CELLS DISORDERS
Downloads
Recent advancements in medical treatments, particularly gene therapy using hematopoietic stem cells (HSCs), have significantly impacted the treatment of inherited blood disorders. HSCs can self-renew and differentiate into blood cells, making them essential for treating conditions like sickle cell anemia, thalassemia, and severe combined immunodeficiency (SCID). This study conducted a literature review on autologous stem cell therapy for genetic blood disorders, analyzing studies from databases such as PubMed and Scopus. Gene therapy corrects genetic defects in HSCs, offering an alternative to allogeneic transplantation by avoiding immune rejection. The therapy involves modifying stem cells in the lab, often through viral vectors or gene-editing tools, and reinfusing them into the patient to produce healthy blood cells long-term. Lentiviral vectors, considered safer than retroviruses, have been particularly effective in treating various conditions, including immunodeficiencies and hemoglobinopathies. The ex vivo gene transfer approach, commonly used for genetic disorders, has shown promise for one-time curative treatments, especially for pediatric diseases. However, early gene therapy efforts, such as the use of gamma-retroviral vectors for SCID, faced complications like leukemia, leading to a shift towards safer lentiviral vectors. Despite its complexity, the procedure has a low failure rate and provides a less risky alternative to traditional allogeneic stem cell transplants. Ultimately, HSC gene therapy holds significant potential for curing genetic blood disorders by permanently altering the stem cells, ensuring long-term benefits and improved treatment outcomes, with ongoing advancements in safety and efficacy.
Aiuti, A., Biasco, L., Scaramuzza, S., Ferrua, F., Cicalese, M. P., Baricordi, C., Dionisio, F., Calabria, A., Giannelli, S., Castiello, M. C., Bosticardo, M., Evangelio, C., Assanelli, A., Casiraghi, M., di Nunzio, S., Callegaro, L., Benati, C., Rizzardi, P., Pellin, D., di Serio, C., Schmidt, M., von Kalle, C., Gardner, J., Mehta, N., Meduva, V., Dow, D. J., Galy, A., Miniero, R., Finocchi, A., Metin, A., Banerjee, P. P., Orange, J. S., Galimberti, S., Valsecchi, M. G., Biffi, A., Montini, E., Villa, A., Ciceri, F., Roncarolo, M. G. and Naldini, L. (2013), “Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome”, Science, Vol. 341 No. 6148.
Aiuti, A., Slavin, S., Aker, M., Ficara, F., Deola, S., Mortellaro, A., Morecki, S., Andolfi, G., Tabucchi, A., Carlucci, F., Marinello, E., Cattaneo, F., Vai, S., Servida, P., Miniero, R., Roncarolo, M. G. and Bordignon, C. (2002), “Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning”, Vol. 296 No. 5577, pp. 2410-3.
Bach, F. H., Albertini, R. J., Joo, P., Anderson, J. L. and Bortin, M. M. (1968), “Bone-marrow transplantation in a patient with the Wiskott-Aldrich syndrome”, Lancet, Vol. 2 No. 7583, pp. 1364-6.
Cavazzana, M., Bushman, F. D., Miccio, A., André-Schmutz, I. and Six, E. (2019), “Gene therapy targeting haematopoietic stem cells for inherited diseases: progress and challenges”, Nature Reviews Drug Discovery, Vol. 18 No. 6, pp. 447-62.
Cavazzana-Calvo, M., Hacein-Bey, S., de Saint Basile, G., Gross, F., Yvon, E., Nusbaum, P., Selz, F., Hue, C., Certain, S., Casanova, J. L., Bousso, P., Deist, F. L. and Fischer, A. (2000), “Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease”, Science, Vol. 288 No. 5466, pp. 669-72.
Dunbar, C. E., High, K. A., Joung, J. K., Kohn, D. B., Ozawa, K. and Sadelain, M. (2018), “Gene therapy comes of age”, Science, Vol. 359 No. 6372.
Gatti, R. A., Meuwissen, H. J., Allen, H. D., Hong, R. and Good, R. A. (1968), “Immunological reconstitution of sex-linked lymphopenic immunological deficiency”, Lancet, Vol. 2 No. 7583, pp. 1366-9.
Giommetti, A. and Papanikolaou, E. (2024), “Advancements in Hematopoietic Stem Cell Gene Therapy: A Journey of Progress for Viral Transduction”, Cells, Vol. 13 No. 12, pp. 1039.
Hacein-Bey-Abina, S., Kalle, C. V., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., Sorensen, R., Forster, A., Fraser, P., Cohen, J. I., de Saint Basile, G., Alexander, I., Wintergerst, U., Frebourg, T., Aurias, A., Stoppa-Lyonnet, D., Romana, S., Radford-Weiss, I., Gross, F., Valensi, F., Delabesse, E., Macintyre, E., Sigaux, F., Soulier, J., Leiva, L. E., Wissler, M., Prinz, C., Rabbitts, T. H., Deist, T. L., Fischer, A. and Cavazzana-Calvo, M. (2003), “LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1”, Science, Vol. 302 No. 5644, pp. 415-9.
Hatzimichael, E. and Tuthill, M. (2010), “Hematopoietic stem cell transplantation”, Stem Cells and Cloning, Vol. 3, pp. 105-17.
Howe, S. J., Mansour, M. R., Schwarzwaelder, K., Bartholomae, C., Hubank, M., Kempski, H., Brugman, M. H., Pike-Overzet, K., Chatters, S. J., de Ridder, D., Gilmour, K. C., Adams, S., Thornhill, S. I., Parsley, K. L., Staal, F. J. T., Gale, R. E., Linch, D. C., Bayford, J., Brown, L., Quaye, M., Kinnon, C., Ancliff, P., Webb, D. K., Schmidt, M., von Kalle, C., Gaspar, H. B. and Thrasher, A. J. (2008), “Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients”, Journal of Clinical Investigation, Vol. 118 No. 9, pp. 3143-50.
Kohn, D. B., Booth, C., Kang, E. M., Pai, S., Shaw, K. L., Santilli, G., Armant, M., Buckland, K. F., Choi, U., Ravin, S. S. D., Dorsey, M. J., Kuo, C. Y., Leon-Rico, D., Rivat, C., Izotova, N., Gilmour, K., Snell, K., Dip, J. X., Darwish, J., Morris, E. C., Terrazas, D., Wang, L. D., Bauser, C. A., Paprotka, T., Kuhns, D. B., Gregg, J., Raymond, H. E., Everett, J. K., Honnet, G., Biasco, L., Newburger, P. E., Bushman, F. D., Grez, M., Gaspar, H. B., Williams, D. A., Malech, H. L., Galy, A. and Thrasher, A. J. (2020), “Lentiviral gene therapy for X-linked chronic granulomatous disease”, Vol. 26 No. 2, pp. 200-6.
Kohn, D. B., Chen, Y. Y. and Spencer, M. J. (2023), “Successes and challenges in clinical gene therapy”, Gene Therapy, Vol. 30, pp. 738-46.
Kohn, D. B., Pai, S. and Sadelain, M. (2013), “Gene therapy through autologous transplantation of gene-modified hematopoietic stem cells”, Biology of Blood and Marrow Transplantation, Vol. 19 No. 1, pp. S64-9.
Kohn, D. B., Sevilla, J., Rao, G., Chitty-Lopez, M., Almarza, D., Terrzas, D., Zubicaray, J., Gonzalez-Vicent, M., Chetty, K., O’Toole, G., Xu-Bayford, J., Nicoletti, E., Fernandes, A., Kuo, C., de Oliveira, S., Moore, T. B., Choi, G., Zeini, M., Mesa-Nunez, C., Thrasher, A. J., Bueren, J. and Schwartz, J. D. (2022), “Interim results from an ongoing phase 1/2 study of lentiviral-mediated ex-vivo gene therapy for pediatric patients with severe leukocyte adhesion deficiency-I (LAD-1)”, Molecules Therapy, Vol. 30, pp. 550.
Magnani, A., Semeraro, M., Adam, F., Booth, C., Dupré, L., Morris, E. C., Gabrion, A., Roudaut, C., Borgel, D., Toubert, A., Clave, E., Abdo, C., Gorochov, G., Petermann, R., Guiot, M., Miyara, M., Moshous, D., Magrin, E., Denis, A., Suarez, F., Lagresle, C., Roche, A. M., Everett, J., Trinquand, A., Guisset, M., Bayford, J. X., Hacein-Bey-Abina, S., Kauskot, A., Elfeky, R., Rivat, C., Abbas, S., Gaspar, H. B., Macintyre, E., Picard, C., Bushman, F. D., Galy, A., Fischer, A., Six, E., Thrasher, A. J. and Cavazzana, M. (2022), “Long-term safety and efficacy of lentiviral hematopoietic stem/progenitor cell gene therapy for Wiskott-Aldrich syndrome”, Nature Medicine, Vol. 28 No. 1, pp. 71-80.
Pai, S., Logan, B. R., Griffith, L. M., Buckley, R. H., Parrott, R. E., Dvorak, C. C., Kapoor, N., Hanson, I. C., Filipovich, A. H., Jyonouchi, S., Sullivan, K. E., Small, T. N., Burroughs, L., Skoda-Smith, S., Haight, A. E., Grizzle, A., Pulsipher, M. A., Chan, K. W., Fuleihan, R. L., Haddad, E., Loechelt, B., Aquino, V. M., Gillio, A., Davis, J., Knutsen, A., Smith, A. R., Moore, T. B., Schroeder, M. L., Goldman, F. D., Connelly, J. A., Porteus, M. H., Xiang, Q., Shearer, W. T., Fleisher, T. A., Kohn, D. B., Puck, J. M., Notarangelo, L. D., Cowan, M. J. and O’Reilly, R. J. (2014), “Transplantation outcomes for severe combined immunodeficiency, 2000-2009”, The New England, Journal of Medicine, Vol. 371 No. 5, pp. 434-46.
Staal, F. J. T., Aiuti, A. and Cavazzana, M. (2019), “Autologous Stem-Cell-Based Gene Therapy for Inherited Disorders: State of the Art and Perspectives”, Frontiers in Pediatrics, Vol. 7.
Copyright (c) 2024 Nurul Faudhan, Yayu Aisida
This work is licensed under a Creative Commons Attribution 4.0 International License.
1. The journal allows the author to hold the copyright of the article without restrictions.
2. The journal allows the author(s) to retain publishing rights without ristrictions.
3. The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution (CC BY).
